Log In
updated 10:20 AM UTC, Dec 13, 2023

Anti-Skin Cancer Drug Approved – Sanofi

Unic Press UK: Sanofi, a renowned French pharmaceutical company said that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on Libtayo – a cancer drug.

With this approval, Libtayo becomes “the first and only treatment approved for certain patients with advanced CSCC (cutaneous squamous cell carcinoma) in the European Union (EU),”  Sanoi said in a press release on April 26, 2019.

CSCC is the second most common form of skin cancer; and Libtayo is for patients suffering from CSCC whose cancerous condition is advanced, but would not face curative surgery or curative radiation.

Libtayo is approved in the U.S. for the treatment of patients with metastatic CSCC or locally advanced CSCC who are not candidates for curative surgery or curative radiation, and in other countries for similar indications.

Tagged under

Leave a Reply